Paracetamol 300mg (as immediate release) paracetamol 700mg (as sustained release) tablets are a pharmaceutical preparation of two different release rates in one tablet. The formulation consists of a pharmaceutical preparation of paracetamol with a strength of 300 mg as an immediate release and 700 mg as a sustained release preparation.
Immediate-release and sustained-release formulations are produced by applying separate formulation strategies. The immediate-release component is formulated to release its active pharmaceutical ingredient in a relatively rapid manner; and the sustained-release component is formulated with an appropriate technology to release its active pharmaceutical ingredient over an extended period of time.
Creating this kind of tablet involves the selection of pharmaceutical grade raw materials, appropriate excipients, process conditions, manufacturing method and quality testing.
Drug Substance Name: Paracetamol This formulation contains the following active pharmaceutical substance: The formulation contains the following dose of the Active Pharmaceutical Ingredient (API): 300mg of Paracetamol (immediate release component) 700mg of Paracetamol (sustained release component)
Where dosage form design has not been involved to provide an extended-release capability, the immediate-release component should be fabricated to enable active drug release from the dosage form. In contrast, the sustained-release component requires a formulation technique to control drug release from the dosage form.
The sustained release component may contain: The addition of suitable excipients and/or release controlling agents in the sustained-release component; The release of the matrix is selected by properties of the polymer, the matrix, the granulometry, the ratio, the compression properties, and even the suitability of the formulation.
The existing release mechanisms provide extra considerations for formulation development. During manufacturing, both controlled-release types need to be maintained in their desired form and yet formulated together to yield a uniform tablet.
Manufacture of Paracetamol 300mg (as Immediate Release), Paracetamol 700mg (as Sustained Release) Tablets Pharmaceutical manufacturing processes are suited to manufacture the paracetamol tablets. Raw materials are usually released to the manufacturer following suitable quality checks.
There may be one or more processing steps involved for each immediate-release and sustained-release component. Formulation ingredients will be processed as needed according to the manufacturing specifications for each formulation ingredient and ultimately assembled into the final formulation.
In manufacturing, it is possible to control parameters such as the material uniformity, the tablet weight, the compression force, the hardness, the thickness, and the physical appearance. Special care should be taken when producing modified-release formulations as the release characteristics can depend on the formulation structure and manufacturing procedure.
QC testing may encompass assay, content uniformity, physical properties, disintegration or dissolution related testing, and other relevant product-specific parameters. Dissolution or release-profile testing is particularly critical to the assessment of the finished product for formulation where the following is a product containing immediate-release and sustained-release components.
Extensive batch records and process controls support product consistency and traceability.
What sets this formulation apart is the presence of immediate release Paracetamol 300mg and sustained release Paracetamol 700mg.
2.4 Tablet formulation and manufacturing The immediate-release part is prepared by means of a standard pharmaceutic process which can generate the active substance to be separated from the tablet without the active substance being affected by the release-controlling processes found in modified-release forms of the tablet.
The same approach is generally used to manufacture controlled-release preparations.1-3 Depending on the aim of the formulation, the release-controlling properties of excipients, factors affecting compression, the physical structure of the tablet and manufacturing variations may all affect the final release profile.
Laboratory Dissolution Testing within the Product Life Cycle Laboratory dissolution testing can be utilized as part of the product development and quality control process to define the drug release profile from the various parts of the delivery form. This enables pharmaceutical companies to set and sustain predetermined product specifications.
Packaging To ensure the quality and identity of Paracetamol 300mg Immediate Release & Paracetamol 700mg Sustained Release Tablets are maintained, appropriate pharmaceutical packaging is vital. Suitable packaging of the product can also assist in the protection of the product during storage, distribution and transportation.
The kind of primary and secondary packaging will be based on the nature of the formulation, stability needs, type of packing and the regulations associated.
Product labels should specify the formulation and the strengths and release attributes of each formulation. The product name, the identity of the formulation, the batch number, the date of manufacture and expiry, the manufacturer and the relevant other details can be added.
Standardized packaging also assists drug manufacturers in ensuring a uniform appearance and branding throughout their drug line up.
Modified-release technologies such as Paracetamol 300mg (as Immediate Release), Paracetamol 700mg (as Sustained Release) Tablets can give a pharmaceutical company some added variety to its product range. Modified-release technologies are a significant part of pharmaceutical formulation development, since they involve particular manufacturing and quality-control skills.
Pharmaceutical manufacturers, franchise and marketing companies, distributor companies can add to the normal tablet range by providing a product with a value-added formulation feature.
A matured pharma portfolio supplier usually takes into account their product quality, formulation technology, production quality, packaging, documentation, supply reliability and the market's demands. Collaborate with an experienced manufacturing company ensures reliable results in respective formulation.
The blending of 2 release characteristics into 1 tablet further exemplifies the importance of formulation technology in today's new product introduction. These products demand a higher level of formulation and process scrutiny than the simple conventional tablet.
Quality is also significant when you have created a formulation comprising immediate-release and sustained-release components. Paracetamol 300mg (as Immediate Release) and 700mg (as Sustained Release) Tablets must be produced with appropriate manufacturing controls to ensure that the characteristics of the individual components are as expected.
A quality-sensitive process starts with pharmaceutical-grade raw materials and can be followed through to formulate development, processing, compression, testing, packaging, and delivery. Controls are implemented to guarantee the final tablet always adheres to the prescribed specifications.
Analytical testing, dissolution profiling, content uniformity testing, physical testing, batch documentation, and process monitoring may be used to ensure the uniformity of products.
For pharma companies wanting to create a robust and differentiated product portfolio, there is a need for the right technology, manufacturing expertise, quality control and a secure supply-chain.
Overall, this formulation is a hybrid of immediate-release and sustained-release pharmaceutical technology within a single tablet. Its intended product success can be achieved with a formulation design, controlled manufacturing, excipient selection, release-profiles tests, quality tests, and adequate packaging.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech